47 results
S-8
EX-99.2
NTBL
Notable Labs Ltd
19 Apr 24
Registration of securities for employees
4:56pm
.
Approved 102 Awards may either be classified as Capital Gain Option (“CGO”) or Ordinary Income Option (“OIO”).
Approved 102 Awards elected
DEF 14A
NTBL
Notable Labs Ltd
16 Feb 24
Definitive proxy
9:00am
the approval of this Plan by the ITA.
Approved 102 Awards may either be classified as Capital Gain Option (“CGO”) or Ordinary Income Option (“OIO
PRE 14A
NTBL
Notable Labs Ltd
5 Feb 24
Preliminary proxy
5:00pm
, and shall be conditioned upon the approval of this Plan by the ITA.
Approved 102 Awards may either be classified as Capital Gain Option (“CGO”) or Ordinary
8-K/A
EX-99.2
NTBL
Notable Labs Ltd
29 Nov 23
Financial Statements and Exhibits
5:00pm
no restricted cash.
Marketable Securities
The Company’s investments in marketable securities have been classified and accounted for as available … income, net. All available-for-sale securities are considered available to support current operations and are classified as current assets.
Deferred
8-K/A
EX-99.4
jccl45
29 Nov 23
Financial Statements and Exhibits
5:00pm
424B3
6jp8 kk0kg7n9metoq
5 Sep 23
Prospectus supplement
6:02pm
CORRESP
fdtz11 cl
26 Jul 23
Correspondence with SEC
12:00am
UPLOAD
3kvulrk
19 Jul 23
Letter from SEC
12:00am
S-4/A
cxoik nx4gjgiz6jot4
30 Jun 23
Registration of securities issued in business combination transactions (amended)
4:38pm
S-4
EX-10.17
fk6fukr
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
glgdpd75bqq57d6n60
11 May 23
Registration of securities issued in business combination transactions
9:09am
6-K
EX-99.2
vrefhsop5ekd
14 Nov 22
VBL Therapeutics Reports Third Quarter 2022 Financial Results
4:19pm
6-K
EX-99.2
4t9juh8394 sifgch
15 Aug 22
VBL Therapeutics Announces Second Quarter 2022 Financial Results
4:07pm
6-K
EX-99.2
q2j3 4od4w7xb
17 May 22
VBL Therapeutics Reports First Quarter 2022 Financial Results
7:00am